Clinical Trials

The clinical development landscape for this compound comprises several completed clinical trials sponsored by Galapagos NV. Initial Phase 1 trials evaluated single and multiple dose pharmacokinetics, metabolism, and drug interaction profiles in healthy subjects. Subsequently, a Phase 2 trial assessed the efficacy and safety of the compound in patients with active Crohn's disease, with all trials on record having been successfully completed.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02048618 Completed
Crohn''s Disease
Galapagos NV
 2014-02 Phase 2
NCT01820806 Completed
Healthy
Galapagos NV
 2013-03 Phase 1
NCT01798979 Completed
Healthy
Galapagos NV
 2013-02 Phase 1
NCT01665924 Completed
Healthy
Galapagos NV
 2012-07 Phase 1

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the GLPG0634 analogue product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

GLPG0634 analogue functions as a selective Janus kinase 1 (JAK1) inhibitor that blocks ATP binding and suppresses downstream STAT protein phosphorylation within the JAK-STAT signaling cascade. This inhibition prevents immune cell activation and reduces systemic proinflammatory cytokine production, thereby attenuating mucosal inflammation in clinical conditions such as Crohn's disease.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.